Skip to main content
Longeveron Inc. logo

Longeveron Inc. — Investor Relations & Filings

Ticker · LGVN ISIN · US54303L2034 US Manufacturing
Filings indexed 462 across all filing types
Latest filing 2026-05-20 Annual Report
Country US United States of America
Listing US LGVN

About Longeveron Inc.

https://www.longeveron.com/

Longeveron Inc. is a clinical-stage biotechnology company that develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product, laromestrocel (Lomecel-B™), is a cell-based therapy designed to repair, regenerate, and restore damaged tissue. Longeveron's clinical development is focused on several key indications, including Hypoplastic Left Heart Syndrome (HLHS), a rare congenital heart defect in infants for which it has an orphan drug designation. Other primary clinical programs target Alzheimer's disease and Aging Frailty. For its Alzheimer's program, the U.S. FDA has granted laromestrocel both Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations. The company's research aims to improve healthspan by addressing unmet medical needs.

Recent filings

Filing Released Lang Actions
ARS
Annual Report
2026-05-20 English
DEFINITIVE ADDITIONAL MATERIALS
Proxy Solicitation & Information Statement
2026-05-20 English
PROXY STATEMENT
Proxy Solicitation & Information Statement
2026-05-20 English
10-Q - Longeveron Inc. (0001721484) (Filer)
Interim / Quarterly Report
2026-05-13 English
424B3 - Longeveron Inc. (0001721484) (Filer)
Prospectus
2026-04-17 English
8-K - Longeveron Inc. (0001721484) (Filer)
Regulatory Filings
2026-04-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.